Core Viewpoint - Basilea Pharmaceutica Ltd has received a USD 6 million award from BARDA to further develop its novel oral antibiotic ceftibuten-ledaborbactam etzadroxil for treating complicated urinary tract infections (cUTIs) [1][2]. Group 1: Funding and Development - The funding from BARDA will support the preparation of clinical phase 3 studies for ceftibuten-ledaborbactam etzadroxil, which addresses the unmet medical need for oral treatment of cUTIs caused by multidrug-resistant bacteria [2]. - Under the contract with BARDA, Basilea could receive up to USD 147 million in additional non-dilutive funding upon completing predefined milestones [2]. Group 2: Product Information - Ceftibuten-ledaborbactam etzadroxil is a combination of a novel broad-spectrum beta-lactamase inhibitor and an oral cephalosporin antibiotic, which has shown effectiveness against resistant strains of Enterobacterales [4]. - The drug has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for cUTI and uncomplicated urinary tract infections, indicating its potential significance in treating these conditions [4]. Group 3: Market Context - Complicated urinary tract infections, including pyelonephritis, are common bacterial infections with increasing resistance, leading to limited effective oral antibiotic options [5]. - Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations effective against resistant Enterobacterales, highlighting the market need for ceftibuten-ledaborbactam etzadroxil [5]. Group 4: Company Overview - Basilea is a commercial-stage biopharmaceutical company founded in 2000, focused on developing innovative drugs for severe bacterial and fungal infections [6][7]. - The company has successfully launched two hospital brands, Cresemba and Zevtera, and has a portfolio of preclinical and clinical anti-infective assets [6][7].

Core Viewpoint - Bicara Therapeutics Inc. has announced a public offering of 7,175,000 shares at $16.00 per share, aiming to raise approximately $150 million to support its clinical and commercial initiatives for ficerafusp alfa, a bifunctional therapy for solid tumors [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants for 2,200,000 shares at a price of $15.9999 each, with gross proceeds expected to be around $150 million before expenses [1]. - The offering is set to close on or about February 26, 2026, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 1,406,250 additional shares at the public offering price [1]. Group 2: Use of Proceeds - Net proceeds will be used to enhance medical and commercial infrastructure for a planned regulatory filing and launch of ficerafusp alfa in the U.S. [2]. - Funds will also support the development of ficerafusp alfa in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, including a less frequent dosing schedule [2]. - Additional uses include covering manufacturing costs for ongoing drug development and early signal-finding for future indication expansion [2]. Group 3: Company Overview - Bicara Therapeutics is focused on developing bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, designed to penetrate tumors by overcoming barriers in the tumor microenvironment [6]. - Ficerafusp alfa combines an EGFR-directed monoclonal antibody with a domain that binds to TGF-β, aiming to reverse the fibrotic and immune-excluded tumor microenvironment [6]. - The therapy is being developed for head and neck squamous cell carcinoma and other solid tumor types, addressing significant unmet medical needs [6].

TOKYO--(BUSINESS WIRE)--HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device 'Alpha DaRT (Diffusing Alpha Radiation Therapy),' developed by Alpha Tau Medical Ltd. (Headquarters: Jerusalem, Israel) has received official approval in Japan. HekaBio led the approval process as the Designated Marketing Authorization Holder (DMAH) and will be responsible for launching the product in the Japanese market. With this approval, Japan becomes the first country in the w ...

SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has entered into the strategic collaboration with Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK). Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Junshi Bio ...

Chief Commercial Officer Matt Houghton said Attruby’s growth has been strongest in first-line patients and attributed momentum to the “exceptional data” for the therapy and the company’s field execution. He emphasized that the company has historically provided a quarterly “new patient start” figure, but said BridgeBio will stop reporting that metric going forward because competitors do not disclose comparable data and continued disclosure could create a competitive disadvantage.BridgeBio reiterated that Att ...

Cytokinetics (NasdaqGS:CYTK) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAlex Xenakis - Research AssociateAndrew Callos - EVP and CCOCory Kasimov - Senior Managing DirectorDiane Weiser - SVP of Corporate Communications and Investor RelationsFady Malik - EVP of Research and DevelopmentJackie Plesset - SMid Cap Biotech Equity Research AssociateJames Condulis - VP of Biotechnology Equity ResearchJoe Pantginis - Managing Director Equity ResearchMaxwell Skor - VP of Biotech Equity Res ...

Day One Biopharmaceuticals (NasdaqGS:DAWN) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsBrittany Socha - Equity Research AssociateCharles N. York II - COO and CFOJeremy Bender - CEOJoey Perrone - Senior Vice President of Finance and Investor RelationsLauren Merendino - CCOMichael Vasconcelles - Head of Research and DevelopmentNick Lorusso - Equity Research Vice PresidentPoorna Kannan - Equity Research AssociateConference Call ParticipantsAndres Y. Maldonado - Senior Biotechnology ...

Day One Biopharmaceuticals (NasdaqGS:DAWN) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker8Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals's fourth quarter and full year 2025 financial and operating results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please be advised that this conference call is being recorded. I would now like to turn the call over to Joey Perrone, Senior Vice Presid ...

FEBRUARY 2026 Fourth Quarter & Full-Year 2025 Financial Results & Corporate Progress In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted ...

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Comp ...